Plain-English translation of NCT07584135 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether JS107, a new cancer drug, works better when combined with another immunotherapy drug and chemotherapy compared to a different immunotherapy drug with chemotherapy alone. The trial is for people with advanced stomach or gastroesophageal junction cancer that has a specific protein marker called CLDN18.2. Researchers want to see if this medication combination can help people live longer and control their cancer better.
Advanced stomach cancer is difficult to treat, and current options don't work well for everyone. This trial exists to see if this new medication combination can offer a more effective first-line treatment option for patients whose tumors have the CLDN18.2 protein marker.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new JS107 medication combination or the standard treatment combination with chemotherapy. You will visit the clinic regularly to receive your medications, have blood tests and scans to monitor how the cancer responds, and report any side effects. The study will continue until the cancer progresses, you experience unacceptable side effects, or you choose to withdraw.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
China